Sunovion's Stedesa treads down monotherapy path
This article was originally published in Scrip
Executive Summary
Sunovion's epilepsy treatment eslicarbazepine acetate has succeeded in two Phase III trials as a monotherapy in adult patients with partial-onset seizures with or without secondary generalization who were not well-controlled by current antiepileptic drugs, marking the first steps towards a possible expansion of the product's use.